Abbott Reports Second-Quarter 2015 Results
- Second-quarter adjusted and GAAP EPS from continuing operations of $0.52, above previous guidance range
- Second-quarter double-digit operational sales growth
- Advances several new technologies in its medical devices and diagnostics businesses

ABBOTT PARK, Ill., July 22, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2015.

  • Second-quarter worldwide sales of $5.2 billion increased 10.8 percent on an operational basis and 2.2 percent on a reported basis. Worldwide sales increased 6.4 percent excluding the impact of 2014 acquisitions and foreign exchange.
  • Diluted EPS from continuing operations on both an adjusted and GAAP basis was $0.52 in the second quarter.
  • Abbott's full-year 2015 adjusted EPS guidance range for continuing operations remains unchanged at $2.10 to $2.20. Projected full-year 2015 EPS for continuing operations under GAAP is $1.50 to $1.60.
  • Second-quarter gross margin ratio was ahead of expectations, primarily driven by continued improvements in Diagnostics and Nutrition.
  • In the second quarter, Abbott received European approval for Absorb GT1TM, which combines the world's first fully dissolving stent with a next-generation delivery catheter; completed submissions for regulatory approval of Absorb in Japan and the U.S.; submitted for U.S. regulatory approval of its FreeStyle® Libre Pro Flash Glucose Monitoring System for professional use; and received U.S. FDA clearance for a first-of-its-kind blood test for its i-STAT® handheld system to aid in detecting early pregnancy in emergency situations.

"We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said Miles D. White, chairman and chief executive officer, Abbott. "We're well on track to achieve our financial objectives for the year despite a challenging currency environment."

SECOND-QUARTER BUSINESS OVERVIEW

Note: Prior year financial results have been adjusted to exclude the sales from Abbott's developed markets branded generics pharmaceuticals and animal health businesses that were sold to Mylan and Zoetis, respectively, in the first quarter 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.

Following are sales by business segment and commentary for the second quarter and first half of the year:

Total Company
($ in millions)

               

% Change vs. 2Q14

   

Sales 2Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total *

 

1,592

 

3,578

 

5,170

 

3.1

 

14.2

 

1.8

 

10.8

 

2.2

Nutrition

 

729

 

988

 

1,717

 

0.6

 

6.3

 

(1.9)

 

3.9

 

(0.8)

Diagnostics

 

350

 

827

 

1,177

 

7.6

 

9.0

 

(4.3)

 

8.7

 

(1.0)

Established Pharmaceuticals

--

 

977

 

977

 

 n/a 

 

46.0

 

31.3

 

46.0

 

31.3

Medical Devices

 

505

 

784

 

1,289

 

3.0

 

3.1

 

(11.2)

 

3.1

 

(6.1)

 

* Total Abbott Sales from continuing operations include Other Sales of $10 million.

 

               

% Change vs. 1H14

   

Sales 1H15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total *

 

3,094

 

6,973

 

10,067

 

2.5

 

13.9

 

2.6

 

10.4

 

2.6

Nutrition

 

1,414

 

1,972

 

3,386

 

--

 

8.7

 

1.2

 

5.0

 

0.7

Diagnostics

 

677

 

1,593

 

2,270

 

6.6

 

7.6

 

(4.6)

 

7.3

 

(1.6)

Established Pharmaceuticals

--

 

1,874

 

1,874

 

 n/a 

 

44.5

 

31.5

 

44.5

 

31.5

Medical Devices

 

990

 

1,525

 

2,515

 

3.3

 

1.4

 

(11.7)

 

2.1

 

(6.3)

 

* Total Abbott Sales from continuing operations include Other Sales of $22 million.

n/a = Not Applicable.

Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates.

Second-quarter 2015 worldwide sales of $5.2 billion increased 10.8 percent on an operational basis and 2.2 percent on a reported basis, including an unfavorable 8.6 percent effect of foreign exchange. Worldwide sales increased 6.4 percent excluding the impact of 2014 acquisitions and foreign exchange, driven by strong performance in Established Pharmaceuticals and Diagnostics.

International sales increased 14.2 percent on an operational basis and 1.8 percent on a reported basis in the second quarter.

Emerging market sales increased 20.6 percent on an operational basis and 10.0 percent on a reported basis in the second quarter. Excluding the impact of 2014 acquisitions and foreign exchange, emerging market sales increased double digits in the quarter.  

Nutrition
($ in millions)         

               

% Change vs. 2Q14

   

Sales 2Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

729

 

988

 

1,717

 

0.6

 

6.3

 

(1.9)

 

3.9

 

(0.8)

Pediatric

 

401

 

567

 

968

 

2.0

 

5.2

 

(1.2)

 

3.9

 

0.1

Adult

 

328

 

421

 

749

 

(1.1)

 

7.7

 

(2.7)

 

3.9

 

(2.0)

 

               

% Change vs. 1H14

   

Sales 1H15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

1,414

 

1,972

 

3,386

 

--

 

8.7

 

1.2

 

5.0

 

0.7

Pediatric

 

786

 

1,144

 

1,930

 

3.2

 

8.4

 

2.3

 

6.3

 

2.7

Adult

 

628

 

828

 

1,456

 

(3.8)

 

9.2

 

(0.3)

 

3.5

 

(1.8)

Worldwide Nutrition sales increased 3.9 percent in the second quarter on an operational basis and decreased 0.8 percent on a reported basis, including an unfavorable 4.7 percent effect of foreign exchange.

Worldwide Pediatric Nutrition sales increased 3.9 percent on an operational basis and 0.1 percent on a reported basis in the quarter, including an unfavorable 3.8 percent effect of foreign exchange. Growth in the quarter was driven by double-digit operational growth in China and several countries in Latin America, partially offset by market dynamics in certain Asian countries. Abbott continues to broaden its pediatric nutrition portfolio in China and recently launched an organic version of its infant formula Eleva TM into the premium segment of the Chinese infant formula market. In the U.S., Abbott provided parents with another formula choice for their babies by launching Similac® Advance® non-GMO.

Worldwide Adult Nutrition sales increased 3.9 percent on an operational basis and decreased 2.0 percent on a reported basis in the quarter, including an unfavorable 5.9 percent effect of foreign exchange. Sales growth in the quarter was led by international performance, including double-digit operational growth in Latin America, as Abbott continues to shape and grow its priority international markets. As expected, U.S. Adult Nutrition sales were impacted by competitive and market dynamics, primarily in the institutional segment.

Diagnostics
($ in millions)

               

% Change vs. 2Q14

   

Sales 2Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total 

 

350

 

827

 

1,177

 

7.6

 

9.0

 

(4.3)

 

8.7

 

(1.0)

Core Laboratory

 

206

 

741

 

947

 

8.6

 

8.4

 

(4.9)

 

8.4

 

(2.3)

Molecular

 

50

 

66

 

116

 

(3.8)

 

18.3

 

2.6

 

8.4

 

(0.3)

Point of Care

 

94

 

20

 

114

 

12.7

 

7.3

 

(1.7)

 

11.6

 

9.8

 

               

% Change vs. 1H14

   

Sales 1H15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total 

 

677

 

1,593

 

2,270

 

6.6

 

7.6

 

(4.6)

 

7.3

 

(1.6)

Core Laboratory

 

391

 

1,422

 

1,813

 

5.3

 

6.9

 

(5.3)

 

6.6

 

(3.2)

Molecular

 

98

 

129

 

227

 

(0.4)

 

14.2

 

0.4

 

7.9

 

--

Point of Care

 

188

 

42

 

230

 

13.7

 

12.6

 

4.5

 

13.5

 

11.9

Worldwide Diagnostics sales increased 8.7 percent in the second quarter on an operational basis and decreased 1.0 percent on a reported basis, including an unfavorable 9.7 percent effect of foreign exchange. This business continues to deliver above-market growth across emerging and developed markets.

Core Laboratory Diagnostics sales increased 8.4 percent in the quarter on an operational basis and decreased 2.3 percent on a reported basis, including an unfavorable 10.7 percent effect of foreign exchange. Above-market sales growth this quarter, including double-digit operational sales growth in emerging markets, was driven by share gains in the U.S. and internationally as this business continues to win key new accounts with its customer-focused solutions.

Molecular Diagnostics sales increased 8.4 percent in the quarter on an operational basis and decreased 0.3 percent on a reported basis, including an unfavorable 8.7 percent effect of foreign exchange. Abbott's core focus area of infectious disease testing, which represents approximately 55 percent of its Molecular Diagnostics sales, increased double digits in the quarter on an operational basis. As expected, U.S. growth was impacted by continued market dynamics in the oncology business and the planned scale down of the genetics business.

Point of Care Diagnostics sales increased 11.6 percent in the quarter on an operational basis as this business continues to build and expand its presence in targeted developed and emerging markets. Sales increased 9.8 percent on a reported basis, including an unfavorable 1.8 percent effect of foreign exchange. In the second quarter, Abbott received U.S. FDA clearance for its i-STAT Total β-hCG test, a first-of-its-kind handheld and whole blood point of care test that can rapidly and accurately detect pregnancy in the early stages, helping doctors make faster treatment decisions for women in emergency situations. In addition, Abbott launched its wireless i-STAT handheld system in Europe, which enables faster decision-making for doctors and enhances workflow by transmitting test results to patient medical records in minutes. 

Established Pharmaceuticals
($ in millions)

Note: Prior year financial results have been adjusted to exclude the sales from the developed markets branded generics pharmaceuticals business, which was sold to Mylan on Feb. 27, 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.

               

% Change vs. 2Q14

   

Sales 2Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

--

 

977

 

977

 

n/a

 

46.0

 

31.3

 

46.0

 

31.3

Key Emerging Markets

 

--

 

727

 

727

 

n/a

 

43.2

 

28.3

 

43.2

 

28.3

Other

 

--

 

250

 

250

 

n/a

 

54.8

 

40.5

 

54.8

 

40.5

 

               

% Change vs. 1H14

   

Sales 1H15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

--

 

1,874

 

1,874

 

n/a

 

44.5

 

31.5

 

44.5

 

31.5

Key Emerging Markets

 

--

 

1,380

 

1,380

 

n/a

 

43.9

 

29.9

 

43.9

 

29.9

Other

 

--

 

494

 

494

 

n/a

 

46.4

 

36.1

 

46.4

 

36.1

Established Pharmaceuticals sales increased 46.0 percent in the second quarter on an operational basis and 31.3 percent on a reported basis, including an unfavorable 14.7 percent effect of foreign exchange.  Excluding the impact of 2014 acquisitions and foreign exchange, sales increased double digits in the quarter.

Key Emerging Markets include India, Russia, China, Brazil and Colombia, along with several additional markets that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 43.2 percent on an operational basis, driven by above-market growth in India, China, and Colombia. Sales increased 28.3 percent on a reported basis, including an unfavorable 14.9 percent effect of foreign exchange.

In Latin America, sales increased double digits in the quarter on an operational basis with and without the impact of the 2014 acquisition of CFR Pharmaceuticals, which broadened Abbott's presence and product portfolio in the region.

Medical Devices
($ in millions)

               

% Change vs. 2Q14

   

Sales 2Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

505

 

784

 

1,289

 

3.0

 

3.1

 

(11.2)

 

3.1

 

(6.1)

Vascular

 

298

 

424

 

722

 

6.0

 

1.5

 

(12.4)

 

3.2

 

(5.6)

Diabetes Care

 

93

 

185

 

278

 

(4.3)

 

10.1

 

(5.8)

 

5.3

 

(5.3)

Medical Optics

 

114

 

175

 

289

 

2.0

 

0.1

 

(13.4)

 

0.8

 

(8.0)

                                 

Vascular Product Lines:

                               

Coronary Devicesa)

 

195

 

363

 

558

 

6.9

 

0.9

 

(12.8)

 

2.7

 

(6.8)

Endovascularb)

 

70

 

62

 

132

 

3.8

 

5.4

 

(9.9)

 

4.6

 

(3.1)

                                 

a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b) Includes vessel closure, carotid stents and other peripheral products.

 

               

% Change vs. 1H14

   

Sales 1H15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

990

 

1,525

 

2,515

 

3.3

 

1.4

 

(11.7)

 

2.1

 

(6.3)

Vascular

 

581

 

839

 

1,420

 

6.3

 

0.5

 

(12.3)

 

2.6

 

(5.5)

Diabetes Care

 

195

 

350

 

545

 

0.3

 

6.0

 

(8.3)

 

4.1

 

(5.4)

Medical Optics

 

214

 

336

 

550

 

(1.5)

 

(1.0)

 

(13.4)

 

(1.2)

 

(9.2)

                                 

Vascular Product Lines:

                               

Coronary Devicesa)

 

380

 

719

 

1,099

 

5.4

 

(0.4)

 

(13.0)

 

1.4

 

(7.4)

Endovascularb)

 

137

 

120

 

257

 

8.0

 

6.1

 

(8.3)

 

7.0

 

(0.2)

                                 

a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b) Includes vessel closure, carotid stents and other peripheral products.

Worldwide Medical Devices sales increased 3.1 percent in the second quarter on an operational basis and decreased 6.1 percent on a reported basis, including an unfavorable 9.2 percent effect of foreign exchange.

Worldwide sales of Vascular products increased 3.2 percent in the quarter on an operational basis and decreased 5.6 percent on a reported basis, including an unfavorable 8.8 percent effect of foreign exchange. Sales of Abbott's MitraClip® structural heart device for the treatment of mitral regurgitation increased double digits globally, including strong momentum in the U.S. as Abbott continues to build and shape the market for this first-in-class device. Abbott recently received European approval for Absorb GT1, which combines the Absorb bioresorbable vascular scaffold with a next-generation delivery catheter. Abbott also completed submissions for regulatory approval of Absorb in Japan and the U.S., and expects to submit for regulatory approval in China in the coming months.

Worldwide Diabetes Care sales increased 5.3 percent in the quarter on an operational basis and decreased 5.3 percent on a reported basis, including an unfavorable 10.6 percent effect of foreign exchange. International sales growth was driven by continued uptake of Abbott's revolutionary new FreeStyle Libre Flash Glucose Monitoring System. In the quarter, Abbott submitted FreeStyle Libre Pro, its professional-use version of FreeStyle Libre, for regulatory approval in the U.S. FreeStyle Libre Pro incorporates the same sensor-based technology as FreeStyle Libre and has the potential to change how healthcare providers manage diabetic patients.

Worldwide Medical Optics sales increased 0.8 percent in the quarter on an operational basis and decreased 8.0 percent on a reported basis, including an unfavorable 8.8 percent effect of foreign exchange. Sales growth in the quarter was impacted by market dynamics in the cataract and refractive businesses. Abbott expects improved sales growth over the rest of the year as it continues to drive adoption of recently launched products.

ABBOTT'S FULL-YEAR 2015 EARNINGS-PER-SHARE GUIDANCE RANGE REMAINS UNCHANGED

Abbott's full-year 2015 guidance range for earnings per share from continuing operations, excluding specified items, remains unchanged at $2.10 to $2.20, representing strong growth at the mid-point of the guidance range.

Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately $0.60 per share. Specified items include intangible amortization expense, charges associated with cost reduction initiatives, and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock.

Including net specified items, projected earnings per share from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) would be $1.50 to $1.60 for the full year 2015.

ABBOTT DECLARES 366TH CONSECUTIVE QUARTERLY DIVIDEND

On June 12, 2015, the board of directors of Abbott declared the company's quarterly dividend of $0.24 per share. Abbott's cash dividend is payable on Aug. 15, 2015, to shareholders of record at the close of business on July 15, 2015.

Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

About Abbott:

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors,'' to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2014, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Second Quarter Ended June 30, 2015 and 2014

(in millions, except per share data)

(unaudited)

 
   

2Q15

 

2Q14

 

% Change

 

Net Sales

 

$5,170

 

$5,057

 

2.2

 
               

Cost of products sold, excluding amortization expense

 

2,218

 

2,288

 

(3.0)

 

Amortization of intangible assets

 

151

 

133

 

13.6

 

Research and development

 

345

 

310

 

11.1

 

Selling, general, and administrative

 

1,727

 

1,649

 

4.8

 

Total Operating Cost and Expenses

 

4,441

 

4,380

 

1.4

 
               

Operating earnings

 

729

 

677

 

7.5

 
               

Interest expense, net

 

17

 

17

 

2.7

 

Net foreign exchange (gain) loss

 

5

 

--

 

n/m

 

Other (income) expense, net

 

(279)

 

2

 

n/m

1)

Earnings from Continuing Operations before taxes

 

986

 

658

 

49.8

 
               

Taxes on Earnings from Continuing Operations

 

200

 

233

 

(14.5)

 

Earnings from Continuing Operations

 

786

 

425

 

85.1

 
               

Earnings (loss) from Discontinued Operations, net of taxes

 

(2)

 

41

 

n/m

2)

               

Net Earnings

 

$784

 

$466

 

68.3

 
               

Net Earnings from Continuing Operations, excluding 

             

Specified Items, as described below

 

$786

 

$741

 

6.1

3)

               

Diluted Earnings per Common Share from:

             
               

Continuing Operations

 

$0.52

 

$0.28

 

85.7

 
               

Discontinued Operations

 

--

 

0.02

 

(100.0)

2)

               

Total

 

$0.52

 

$0.30

 

73.3

 
               

Diluted Earnings per Common Share from Continuing 

             

Operations, excluding Specified Items, as described below

 

$0.52

 

$0.49

 

6.1

3)

               

Average Number of Common Shares Outstanding

             

Plus Dilutive Common Stock Options 

 

1,504

 

1,517

     
 

NOTES:

 

See tables below for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes below.

 

1)

2015 Other (income) expense includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.

   

2)

2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations.

   

3)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of less than $1 million as intangible amortization expense, expenses associated with cost reduction initiatives and expenses related to acquisitions were offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

   
 

2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $316 million, or $0.21 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

First Half Ended June 30, 2015 and 2014

(in millions, except per share data)

(unaudited)

 
   

1H15

 

1H14

 

% Change

 

Net Sales

 

$10,067

 

$9,812

 

2.6

 
               

Cost of products sold, excluding amortization expense

 

4,299

 

4,562

 

(5.8)

 

Amortization of intangible assets

 

307

 

260

 

18.2

 

Research and development

 

658

 

679

 

(3.0)

 

Selling, general, and administrative

 

3,464

 

3,269

 

6.0

 

Total Operating Cost and Expenses

 

8,728

 

8,770

 

(0.5)

 
               

Operating earnings

 

1,339

 

1,042

 

28.4

 
               

Interest expense, net

 

33

 

37

 

(10.5)

 

Net foreign exchange (gain) loss

 

(49)

 

1

 

n/m

 

Other (income) expense, net

 

(284)

 

5

 

n/m

1)

Earnings from Continuing Operations before taxes

 

1,639

 

999

 

63.9

 
               

Taxes on Earnings from Continuing Operations

 

324

 

350

 

(7.7)

 

Earnings from Continuing Operations

 

1,315

 

649

 

102.5

 
               

Earnings from Discontinued Operations, net of taxes

 

25

 

192

 

(87.1)

 

Gain on Sale of Discontinued Operations, net of taxes

 

1,736

 

--

 

n/m

 

Net Earnings from Discontinued Operations, net of taxes

 

1,761

 

192

 

n/m

2)

               

Net Earnings

 

$3,076

 

$841

 

n/m

 
               

Net Earnings from Continuing Operations, excluding 

             

Specified Items, as described below

 

$1,505

 

$1,276

 

17.9

3)

               

Diluted Earnings per Common Share from:

             
               

Continuing Operations

 

$0.87

 

$0.42

 

107.1

 
               

Discontinued Operations

 

1.16

 

0.13

 

n/m

2)

               

Total

 

$2.03

 

$0.55

 

n/m

 
               

Diluted Earnings per Common Share from Continuing 

             

Operations, excluding Specified Items, as described below

 

$0.99

 

$0.83

 

19.3

3)

               

Average Number of Common Shares Outstanding

             

Plus Dilutive Common Stock Options 

 

1,511

 

1,532

     
 

NOTES:

 

See tables below for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes below.

 

1)

2015 Other (income) expense includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.

   

2)

2015 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect the after-tax gain of $1.736 billion on the sale of the developed markets branded generics pharmaceuticals and animal health businesses to Mylan on Feb. 27, 2015 and Zoetis on Feb. 10, 2015, respectively; the first-quarter financial results from these businesses up to the date of sale; and a favorable adjustment to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations. 

   
 

2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations and the developed markets branded generics pharmaceuticals business.

   

3)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $190 million, or $0.12 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

   
 

2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $627 million, or $0.41 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

NON-GAAP RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING OPERATIONS

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Second Quarter Ended June 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)

 
   

2Q15

   

As
Reported
(GAAP) 

 

Specified
Items

 

As
Adjusted

 

% to
Sales

                 

Intangible Amortization

 

$151

 

($151)

 

--

   

Gross Margin

 

2,801

 

185

 

$2,986

 

57.8%

R&D

 

345

 

(20)

 

325

 

6.3%

SG&A

 

1,727

 

(67)

 

1,660

 

32.1%

Other (Income) Expense, Net

 

(279)

 

287

 

8

   

Earnings from Continuing Operations before taxes 

 

986

 

(15)

 

971

   

Taxes on Earnings from Continuing Operations

 

200

 

(15)

 

185

   

Net Earnings from Continuing Operations

 

786

 

--

 

786

   

Diluted Earnings per Share from Continuing Operations

 

$0.52

 

--

 

$0.52

   

 

Specified items reflect intangible amortization expense of $151 million and other expenses of $121 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.

   

2Q14

   

Historical GAAP
Adj for Disc Ops1)

 

Specified
Items

 

As
Adjusted 

 

% to
Sales

                 

Intangible Amortization

 

$133

 

($133)

 

--

   

Gross Margin

 

2,636

 

160

 

2,796

 

55.3%

R&D

 

310

 

(1)

 

309

 

6.1%

SG&A

 

1,649

 

(95)

 

1,554

 

30.7%

Other (Income) Expense, Net

 

2

 

(2)

 

--

   

Earnings from Continuing Operations before taxes

 

658

 

258

 

916

   

Taxes on Earnings from Continuing Operations

 

233

 

(58)

 

175

   

Net Earnings from Continuing Operations

 

425

 

316

 

741

   

Diluted Earnings per Share from Continuing Operations

 

$0.28

 

$0.21

 

$0.49

   
   

1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $133 million and other expenses, primarily associated with cost reduction initiatives of $125 million, as well as tax expense of $101 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

First Half Ended June 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)

 
   

1H15

   

As
Reported
(GAAP) 

 

Specified
Items

 

As
Adjusted

 

% to
Sales

                 

Intangible Amortization

 

$307

 

($307)

 

--

   

Gross Margin

 

5,461

 

371

 

$5,832

 

57.9%

R&D

 

658

 

(22)

 

636

 

6.3%

SG&A

 

3,464

 

(109)

 

3,355

 

33.3%

Other (Income) Expense, Net

 

(284)

 

282

 

(2)

   

Earnings from Continuing Operations before taxes 

 

1,639

 

220

 

1,859

   

Taxes on Earnings from Continuing Operations

 

324

 

30

 

354

   

Net Earnings from Continuing Operations

 

1,315

 

190

 

1,505

   

Diluted Earnings per Share from Continuing Operations

 

$0.87

 

$0.12

 

$0.99

   

 

Specified items reflect intangible amortization expense of $307 million and other expenses of $200 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.

   

1H14

   

Historical GAAP
Adj for Disc Ops1)

 

Specified
Items

 

As
Adjusted 

 

% to
Sales

                 

Intangible Amortization

 

$260

 

($260)

 

--

   

Gross Margin

 

4,990

 

342

 

5,332

 

54.3%

R&D

 

679

 

(51)

 

628

 

6.4%

SG&A

 

3,269

 

(180)

 

3,089

 

31.5%

Other (Income) Expense, Net

 

5

 

(4)

 

1

   

Earnings from Continuing Operations before taxes

 

999

 

577

 

1,576

   

Taxes on Earnings from Continuing Operations

 

350

 

(50)

 

300

   

Net Earnings from Continuing Operations

 

649

 

627

 

1,276

   

Diluted Earnings per Share from Continuing Operations

 

$0.42

 

$0.41

 

$0.83

   
   

1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $260 million and other expenses, primarily associated with cost reduction initiatives of $317 million, as well as tax expense of $154 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS

A reconciliation of the second-quarter tax rates for continuing operations for 2015 and 2014 is shown below:

     

2Q15

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$986

 

$200

 

20.2%

 

Specified items

 

(15)

 

(15)

     

Excluding specified items

 

$971

 

$185

 

19.0%

 
                 
                 
     

2Q14

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$658

 

$233

 

35.4%

1)

Specified items

 

258

 

(58)

     

Excluding specified items

 

$916

 

$175

 

19.0%

 
   

1)

Reported tax rate on a GAAP basis includes the impact of tax expense of $101 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2015 and 2014 is shown below:

     

1H15

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$1,639

 

$324

 

19.7%

 

Specified items

 

220

 

30

     

Excluding specified items

 

$1,859

 

$354

 

19.0%

 
                 
                 
     

1H14

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$999

 

$350

 

35.0%

2)

Specified items

 

577

 

(50)

     

Excluding specified items

 

$1,576

 

$300

 

19.0%

 
   

2)

Reported tax rate on a GAAP basis includes the impact of tax expense of $154 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott's 2Q 2015 Earnings Infographic

Photo - http://photos.prnewswire.com/prnh/20150721/239121-INFO

 

SOURCE Abbott

For further information: Abbott Financial: Scott Leinenweber, (224) 668-0791, Michael Comilla, (224) 668-1872, Jeffrey Byrne, (224) 668-8808, Abbott Media: Scott Stoffel, (224) 668-5201, Elissa Maurer, (224) 668-3309
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

yesno
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

yesno